During a hearing in front of the Senate’s HELP committee, Susan Monarez addressed her controversial firing and recalled a ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

The multi-billion, multi-year investment comes as many of GSK’s pharma peers pull away from the U.K., either suspending or ...

In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss ...

From a small team of researchers and skipped salaries, CEO Michelle Xia has steered Akeso to become one of the most exciting ...

A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a ...

Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate ...

This manufacturing site in Richmond, Virginia, is the first of four projects that Eli Lilly plans to reveal this year as part ...

The over-representation of males and Hispanic patients in Eli Lilly’s Phase III ATTAIN-1 study could explain why orforglipron ...

The White House is clamping down on pharma’s ability to buy new molecules from Chinese biotechs; Sanofi, Merck and others ...

Transparency doesn’t drive people away. It attracts the right ones and keeps them committed. Leadership coach Angela Justice ...

While the FDA is trumpeting this new initiative as “sweeping reforms” to the way drug companies can advertise, experts say ...